Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study
Maintaining ⩾85% RDI during first-line platinum chemotherapy may offer clinical benefits and warrants further validation in larger cohorts.
Authors
- Aldo Caltavituro (ORCID: https://orcid.org/0000-0001-5952-4333)
- Pietro De Placido (ORCID: https://orcid.org/0000-0002-1979-5400)
- Carmine De Angelis (ORCID: https://orcid.org/0000-0003-1158-4630)
- Giuseppe Neola
- R. Buonaiuto
- M. Garassino
- Marianna Tortora (ORCID: https://orcid.org/0000-0002-9853-9594)
- Margaret Ottaviano (ORCID: https://orcid.org/0000-0001-9589-0808)
- Erica Pietroluongo (ORCID: https://orcid.org/0000-0003-2370-2139)
- Grazia Arpino
- Roberto Bianco
- Mario Giuliano
- Giovannella Palmieri
- Alberto Servetto
Institutions
- Harvard University (US)
- Regione Campania (IT)
- University of Chicago (US)
- Federico II University Hospital (IT)
- Dana-Farber Cancer Institute (US)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Scuola Superiore Meridionale (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/17588359251411122
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00